In short
This article discusses a clinical trial investigating the effects of switching narcolepsy patients from high-sodium oxybate to XYWAV, a drug containing magnesium oxybate and other oxybate salts. The study aims to evaluate changes in blood pressure and other related factors in participants with narcolepsy who make this switch.
At a glance
- Study Type
- Open-label, multicenter switch study
- Main Objective
- Evaluate impact of switching from high-sodium oxybate to XYWAV on 24-hour ambulatory systolic blood pressure
- Participants
- Adults (18-70 years) with narcolepsy Type 1 or 2
- Key Inclusion Criteria
- Taking high-sodium oxybate 6-9 g/night for at least 6 weeks; specific blood pressure readings
- Key Exclusion Criteria
- Unstable medical conditions, renal impairment, resistant hypertension, significant cardiovascular disease
- Primary Endpoint
- Change in 24-hour average systolic blood pressure from baseline to end of treatment
- Secondary Endpoints
- Changes in daytime, seated resting, and nighttime average systolic blood pressure
- Study Drug
- XYWAV (containing sodium, calcium, magnesium, and potassium oxybate)
- Maximum Daily Dose
- 9 grams
- Treatment Duration
- Up to 6 weeks
What is XYWAV?
XYWAV is a new medication designed to treat narcolepsy. It is also known as JZP258 or Oxybate Mixed-Salt Formulation. XYWAV contains a combination of four active substances: sodium oxybate, calcium oxybate, magnesium oxybate, and potassium oxybate. This formulation is different from the previously used high-sodium oxybate medications, as it aims to reduce the sodium content while maintaining effectiveness.
How XYWAV Works
XYWAV works by affecting the central nervous system to help regulate sleep patterns in people with narcolepsy. The oxybate compounds in XYWAV act on specific receptors in the brain to improve nighttime sleep and reduce daytime sleepiness. By using a mix of different oxybate salts, XYWAV provides the therapeutic benefits of oxybate while reducing the overall sodium intake.
Conditions Treated by XYWAV
XYWAV is primarily used to treat narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden attacks of sleep. It can be used for both Type 1 and Type 2 narcolepsy. Type 1 Narcolepsy: This form of narcolepsy is associated with sudden loss of muscle tone (cataplexy) and is caused by a lack of hypocretin in the brain. Type 2 Narcolepsy: This type does not involve cataplexy but still causes excessive daytime sleepiness.
Dosage and Administration
XYWAV is an oral solution taken twice nightly. The maximum daily dose is 9 grams, divided into two doses. The exact dosage may vary depending on the individual patient's needs and response to treatment. It's important to follow the prescribing doctor's instructions carefully when taking XYWAV.
Eligibility Criteria for XYWAV Treatment
To be eligible for XYWAV treatment, patients typically need to meet certain criteria: Age between 18 and 70 years Diagnosed with Type 1 or Type 2 narcolepsy according to ICSD-3 or DSM-5 criteria Previously treated with high-sodium oxybate at a dose of 6 to 9 g/night for at least 6 weeks If taking other medications that affect blood pressure, the dosage should be stable for at least 2 months Systolic blood pressure between 130 and 155 mm Hg Diastolic blood pressure not greater than 95 mm Hg
Potential Benefits of XYWAV
The main potential benefit of XYWAV is its lower sodium content compared to previous oxybate treatments. This is particularly important for patients with narcolepsy who may be at risk of high blood pressure. A clinical study is being conducted to evaluate the impact of switching from high-sodium oxybate to XYWAV on blood pressure in narcolepsy patients. The study aims to measure changes in: 24-hour average systolic blood pressure Daytime average systolic blood pressure Seated resting average systolic blood pressure Nighttime average systolic blood pressure These measurements will help determine if XYWAV can effectively treat narcolepsy while potentially reducing the risk of high blood pressure associated with high-sodium treatments.
Precautions and Contraindications
XYWAV may not be suitable for everyone. Some conditions that may prevent a person from using XYWAV include: Unstable medical conditions or psychiatric disorders Renal impairment with creatinine clearance less than 45 mL/min Resistant hypertension (high blood pressure that's difficult to control) Significant cardiovascular disease Atrial fibrillation Recent or current substance use disorders History of phenylketonuria or hypersensitivity to phenylalanine-derived products Succinic semi-aldehyde dehydrogenase deficiency It's crucial to discuss your full medical history with your doctor before starting XYWAV treatment.